会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • QUINOXALINE COMPOUNDS, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND A PROCESS FOR THE PREPARATION THEREOF
    • 喹啉化合物,含有它们的药物制剂及其制备方法
    • WO1997019934A1
    • 1997-06-05
    • PCT/HU1996000072
    • 1996-11-28
    • CHINOIN GYOGYSZER ÉS VEGYÉSZETI TERMÉKEK GYARA RT.BATA, ImreBATORI, SándorBENCE, JuditBÖCSKEI, ZsoltCSIKOS, ÉvaERDO"e;, SándorGÖNCZI, CsabaHERMECZ, IstvánHÉJA, GergelyLAKICS, ViktorMAJLATH, CsillaMOLNAR, PéterPODANYI, BenjaminRITZ, ImolaSANTANÉ, Csutor, AndreaSZO"e;KÉNÉ, Szappanos, AndreaSZVOBODA, Györgyné
    • CHINOIN GYOGYSZER ÉS VEGYÉSZETI TERMÉKEK GYARA RT.
    • C07D241/44
    • C07D241/54C07D241/44
    • The invention relates to compounds of general formula (I) and salts, tautomeric forms and N-oxides thereof in which formula: Z means hydrogen, hydroxy, C1-4 alkyl, C7-9 phenylalkyl, optionally substituted phenyl, COOC1-4 alkyl, C2-14 acyl, C1-4 alkylsulphonyl, trifluoromethyl-sulphonyl, optionally substituted benzoyl, optionally substituted phenyl-sulphonyl group; Y means hydrogen, or optionally substituted amino group, or Y and Z form together a -CO-O- group, where Y and Z mean together a valency bond, or Y and Y mean together a valency bond, and at the same time Z means hydrogen, hydroxy, C1-4 alkyl, C7-9 phenylalkyl, optionally substituted phenyl, COOC1-4 alkyl, C2-14 acyl, C1-4 alkylsulphonyl, trifluoromethyl-sulphonyl, optionally substituted benzoyl, optionally substituted phenyl-sulphonyl group; X and X mean together =O, or =S, or X means hydrogen, -NHR or -WR groups, and at the same time X means hydrogen, or X and X together form a valency bond, X means hydrogen, C1-4 alkyl, C7-9 phenylalkyl, optionally substituted phenyl, R and R mean hydrogen, halogen, C1-4 alkyl, trifluoromethyl, ciano, mercapto or sulphonylamido group, R means hydrogen or nitro group, R means hydrogen or hydroxy group, R means hydrogen, C1-4 alkyl, C7-9 phenylalkyl group, W means oxygen or sulfur with the proviso, that a) if at least one of the substituents of R , R and R is different from hydrogen or b) if the meaning of Z and Z is hydrogen and R means 6-chloro, R means hydrogen, R has a different meaning from 7-chloro, or R means 6-methyl, R means hydrogen, R has a different meaning from 7-methyl; compounds of general formula (I) show a significant activity at the glycine binding site of the NMDA-receptor, therefore they can be used as active ingredients of pharmaceutical compositions.
    • 本发明涉及通式(I)的化合物及其盐,互变异构形式和N-氧化物,其中式:Z 1表示氢,羟基,C 1-4烷基,C 7-9苯基烷基,任选取代的苯基,COOC1- C 1-4烷基磺酰基,三氟甲磺酰基,任选取代的苯甲酰基,任选取代的苯基磺酰基; Y 1表示氢或任选取代的氨基,或Y 1和Z 1一起形成-CO-O-基团,其中Y 2和Z 2表示价键,或 Y 1和Y 2均表示价键,同时Z 2表示氢,羟基,C 1-4烷基,C 7-9苯基烷基,任选取代的苯基,COOC 1-4烷基, 14酰基,C 1-4烷基磺酰基,三氟甲基磺酰基,任选取代的苯甲酰基,任选取代的苯基磺酰基; X 1和X 2均表示= O或= S或X 1表示氢,-NHR 4或-WR 5基团,同时X 2表示氢 或X 2和X 3一起形成价键,X 3表示氢,C 1-4烷基,C 7-9苯基烷基,任选取代的苯基,R 1和R 2表示氢, 卤素,C 1-4烷基,三氟甲基,碳原子,巯基或磺酰氨基,R 3表示氢或硝基,R 4表示氢或羟基,R 5表示氢,C 1-4烷基, 9苯基烷基,W表示氧或硫,条件是a)如果R 1,R 2和R 3的至少一个取代基不同于氢或b)如果Z的含义 1和Z 2是氢,R 1表示6-氯,R 3表示氢,R 2与7-氯不同,或者R 1表示6-甲基, R 3表示氢,R 2与7-甲基具有不同的含义; 通式(I)的化合物在NMDA受体的甘氨酸结合位点显示出显着的活性,因此它们可以用作药物组合物的活性成分。
    • 6. 发明申请
    • TRIAZOLO-QUINOLIN DERIVATIVES USEFUL AS ADENOSINE RECEPTOR LIGANDS
    • 作为腺苷受体配体的TRIAZOLO-QUINOLIN衍生物有用
    • WO2003053968A1
    • 2003-07-03
    • PCT/HU2002/000143
    • 2002-12-17
    • SANOFI-SYNTHELABOARÁNYI, PéterBALÁZS, LászlóBÁTORI, SándorBENCE, JuditBOÉR, KingaHAJDÚ, FélixKAPUI, ZoltánMIKUS, EndreSZABÓ, TiborT. NAGY, LajosTÍMÁRI, GézaURBÁN-SZABÓ, KatalinWALCZ, Erzsébet
    • ARÁNYI, PéterBALÁZS, LászlóBÁTORI, SándorBENCE, JuditBOÉR, KingaHAJDÚ, FélixKAPUI, ZoltánMIKUS, EndreSZABÓ, TiborT. NAGY, LajosTÍMÁRI, GézaURBÁN-SZABÓ, KatalinWALCZ, Erzsébet
    • C07D471/04
    • C07D471/04C07D215/54C07D215/56
    • The present invention relates to adenosine A¿3? receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and theirs salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and to the preparation thereof.
    • 三唑并喹啉衍生物是新的。 式(I)的三唑并喹啉衍生物,其盐,溶剂合物和旋光异构体及其盐或溶剂化物是新的。 R 1> R 2> H或直链或支链的1-4C烷基; R 3>直链或支链的1-4C烷基,苯基,噻吩基,呋喃基(任选被至少一个直链或支链的1-4C烷基,直链或支链的1-4C烷氧基或卤素取代),H,5-6元杂芳环 含有一个氮原子和一个氧原子或一个氮原子和一个硫原子的1-3元原子或5元杂芳环(任选被至少一个直链或支链的1-4C烷基,直链或支链的1-4C烷氧基 或卤素); R 4>和R 5> H; R 4> + R 5> 1,3-丁二烯基(任选被亚甲二氧基或至少一个直链或支链的1-4C烷基,直链或支链的1-4C烷氧基,OH或卤素取代); R 6> H,氰基,氨基羰基,1-4C烷氧基羰基或羧基; R 7>苯基,苄基,噻吩基,呋喃基(全部由亚甲二氧基或至少一个直链或支链的1-4C烷基,直链或支链的1-4C烷氧基,OH,三氟甲基,氰基或卤素取代),H,直链或支链 1-4C烷基或1-4C亚烷基(任选被苯基取代),氨基,一或二烷基氨基,含有1-3个N原子的5-6元杂芳族环或含有一个氮原子和一个氧原子的5元杂芳环,或 一个氮原子和一个硫原子(任选被至少一个直链或支链的1-4C烷基,直链或支链的1-4C烷氧基或卤素取代); X:-CH 2 - , - NH - , - NR 1 - , - S,O,磺基或磺氧基; R 1> 2>直链或支链的1-4C烷基或3-6C环烷基; 还包括:(1)(I)的制备; 和(2)式(II)的新的中间体1,2-二氨基吡啶盐。 活动: Nephrotropic; 抗过敏; 抗炎; 皮肤; 银屑病; 低血压; 眼科; 降血糖; 平喘; 免疫抑制; 抗风湿; 抑制细胞生长; Vasotropic; 抗心律不整。 作用机制:腺苷A 3受体拮抗剂。 使用HEK-293细胞测试化合物的腺苷A 3受体拮抗活性。 描述测试细节,但没有给出具体化合物的结果。 通常化合物(I)显示K i为3.5和0.78nM。